Abstract
Serum samples were collected pre- and post-booster vaccination with Comirnaty in 626 participants (aged ≥ 50 years) who had received two Comirnaty doses < 30 days apart, two Comirnaty doses ≥ 30 days apart or two Vaxzevria doses ≥ 30 days apart. Irrespective of primary vaccine type or schedule, spike antibody GMTs peaked 2–4 weeks after second dose, fell significantly ≤ 38 weeks later and rose above primary immunisation GMTs 2–4 weeks post-booster. Higher post-booster responses were observed with a longer interval between primary immunisation and boosting.
Highlights
Serum samples were collected pre- and post-booster vaccination with Comirnaty in 626 participants who had received two Comirnaty doses < 30 days apart, two Comirnaty doses ≥ 30 days apart or two Vaxzevria doses ≥ 30 days apart
COVID-19 vaccine responses after extended immunisation schedules In England, the UK Health Security Agency initiated an evaluation of vaccine responses in adults aged 50 years and older who received the Comirnaty or Vaxzevria vaccines as part of the national immunisation programme to compare short vs longer interval vaccine schedules and monitor antibody waning over time [7]
We describe the antibody kinetics after primary immunisation and booster vaccination in adults aged 50 years and older who were vaccinated as part of the national COVID-19 immunisation programme
Summary
These early data show a rapid serological response to boosting with Comirnaty, with significantly higher antibody responses than those observed after the second dose. Serological assessments provide a measure of vaccine responses, but do not take into account innate or cellular immunity which play an important role in protection [9,10]. Figure SARS-CoV-2 S antibody responses < 3 weeks before the second dose of the primary COVID-19 vaccination, after the second dose and after booster dose vaccination in previously uninfected individuals, London, United Kingdom, September– December 2021(n = 626)a
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
